raghu kannan “the new gold standard in companion diagnostics”
Post on 18-Jan-2016
233 Views
Preview:
TRANSCRIPT
Golden Diagnostics
Raghu Kannan
“THE NEW GOLD STANDARD IN
COMPANION DIAGNOSTICS”
Introductory Slide
Current methods of detectionIHC: Dako –in accuratePCR –amplifies all genes FISH –works well; however, microscopic visualization of tumor regions is difficult
First Target: NSCLCQuantify proteinsQuantify genesEffective treatment plan
Detects and quantifies proteins in tumor tissue.
Unmet Market or Clinical Need
Lung Cancer (2014) Incidence 221,200; Mortality: 158,040
The heterogeneity of NSCLC makes effective treatment dependent on knowledge of the patient’s tumor biomarkers (and mutations)
Cost of targeted therapy: $100,000
A diagnostic test platform that enables identification and quantitation of all types of tumor biomarkers (and mutation) is needed
Value Proposition
Platform Technology: Gold nanorod mediated targeted histochemistry” (GNR-HC).
Can identify and precisely quantify biomarkers in human tissues Highly sensitive.Can detect and quantify all classes of tumor biomarkers (e.g., proteins, mutations, gene fusion, copy number variants)
Business Model / Customer Development / Delivering Your SolutionBusiness model.
Diagnostic kit supplied to pathology laboratories.Oncologists –order to provide effective treatment plan.Pharmaceutical companies use as companion diagnostics.
Market strategyStart up: Golden DiagnosticsIDE; PMA pathway$250K for Pre-IDE phase$1-$1.5 million for IDE and PMA approval
Intellectual Property / Proprietary Technology
Building Management Teams and Advisory Board / Network DevelopmentRaghu Kannan –Business
development and nanotechnologyCo-founder of three start-ups; raised more than $3 million in funding.
Gerald Arthur –Board Certified PathologistPartners and potential partners
Regulatory specialists –Dr. Anandhi UpendranIndustry contacts –Eli Lilly for providing human samples and expertise
Financial Projections and Milestones
top related